Canaccord lowered the firm’s price target on Pulmonx (LUNG) to $15 from $16 and keeps a Buy rating on the shares. The firm said they reported a relatively in-line first quarter and the company reiterated the 2025 guidance that it already provided. The company is confident that its OUS business in the near term will also not be impacted, expecting continued orders from China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG: